LM-302 is under clinical development by Bristol-Myers Squibb and currently in Phase I for Esophageal Cancer. According to GlobalData, Phase I drugs for Esophageal Cancer have an 80% phase transition ...

Vemurafenib is under clinical development by F. Hoffmann-La Roche and currently in Phase II for Craniopharyngioma. According to GlobalData, Phase II drugs for Craniopharyngioma does not have ...

Vemurafenib is under clinical development by F. Hoffmann-La Roche and currently in Phase II for Sarcomas. According to GlobalData, Phase II drugs for Sarcomas have a 27% phase transition success rate ...

Denosumab biosimilar is under clinical development by Samsung Bioepis and currently in Phase III for Post Menopausal Osteoporosis.

GlobalData’s clinical trials dashboard is powered by the Pharma Intelligence Center, which boasts a highly comprehensive source of Clinical Trials collated from numerous government, non-government and ...

XBiotech has said it will investigate the results of its rheumatoid arthritis trial after finding irregularities in its Phase II trial.

This seed funding comes after GEMMABio secured $100m in October through a partnership with Brazilian supplier Fiocruz.

The FDA initially rejected the marketing application for Alhemo in 2022, asking for additional data on dosing and monitoring.

RAPT Therapeutics and Shanghai Jemincare Pharmaceutical have signed an exclusive agreement for RPT904 to treat various allergic conditions.

AstraZeneca has gained approval from the European Commission for its oral therapy, Tagrisso (osimertinib), to treat adults with NSCLC.

Though still below boom levels seen a few years ago, 2024 compares favourably to 2023, and signs suggest that growth will continue into 2025.

Lilly’s Zepbound has become the first prescription medicine approved to treat adults with moderate to severe obstructive sleep apnoea (OSA) and obesity.